The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload.
Digital Pathology, seen as a great potential for productivity enhancement, has not fully delivered on that promise. Some ROI studies have, at best, demonstrated marginally positive return on investment with others demonstrating negative impact on cost post implementation.
We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Deciphex plan to be at the forefront of this revolution with cleverly positioned solutions, that deliver on the biggest problems facing pathology today.
Ergonomic workflows integrated with artificial intelligence to optimise pathologist productivity is key in delivery of Deciphex solutions.
Deciphex places the emphasis on triaging out of high volume, low complexity samples, allowing pathologists the time needed to focus on difficult, more challenging content.
Deciphex are focussed on integrating the highest quality proprietary annotated data sets for deep learning development and validation.
Deciphex targets Human Gastrointestinal and Toxicologic Pathology use cases rather than attempting a one size fits all approach.
Donal is an experienced corporate officer in the technology and diagnostics sectors, having 20 years of business leadership experience from start-up through to large corporate enterprise. Donal has founded three companies and has senior management experience in Slidepath, Genetix, Leica Microsystems and Leica Biosystems. Donal has considerable M&A experience with experience of both trade sales and acquisitions.
Mark is an expert in image analysis, machine learning and pattern recognition. He has over 30 years’ experience developing slide scanning and image analysis products for cytogenetics and pathology. Mark has considerable experience in diagnostic product regulation and intellectual property protection, authoring several technology patents.
Runjan is an experienced Anatomical Pathologist/Histopathologist with speciality interests in GI and pancreatic pathology, who has held chairs of Pathology in South Africa and Glasgow. He was most recently the Program Medical Director and Pathologist (Chief/Professor) of Pathology at University Health Network and University of Toronto. He also was Head of Translational Pathology at the University of Oxford and Head of Histopathology at Brighton and Sussex University Hospitals Trust.
Mairin (PhD, MBA) is an experienced COO with >15 years experience in startups and academia. She has considerable experience in operational management, research funding, research programme management and generating IP portfolios. As COO, she also manages all company day to day activities, including defining business strategy, financial, HR and IP.
Andrea is an experienced software consultant having 10+ years of proven track record covering a wide range of technical roles, using different technologies and paradigms. Andrea has delivered cutting-edge cloud solutions in a range fields such as GIS, Healthcare and Finance. Andrea has worked as senior software architect in Slidepath and Leica Biosystems developing significant knowledge of the pathology sector.
Shane is an experienced, results-oriented manager with over a decade of experience in Digital Pathology. Shane has worked in regulated multinationals since 2008 and has held multiple management and leadership roles since 2014. Shane believes all problems can ultimately be solved through Constant Improvement and that efficiency in process and workflow can enable people to focus on critical tasks rather than the mundane.
Colin has worked in the Digital Pathology sector for 17 years, bringing with him a wealth of experience in the design and delivery of innovative software products for the Healthcare, Life Science & Academic segments. Colin has worked in both dynamic Start-Up and Large Corporate organisations, fulfilling a broad remit of customer-facing roles in Business Development, Sales, Commercial Marketing and Product Management.
Deciphex is pleased to announce its success, in collaboration with partners Oncomark and UCD, in securing a €3m Government of Ireland, Disruptive Technologies Innovation Fund award to pursue its ongoing research program in cancer prognostics.
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data.
Deciphex and Charles River Laboratories International, Inc. (NYSE: CRL) have jointly announced today that they are the first in the industry to offer clients Good Laboratory Practice (GLP) validated digital peer review, using Deciphex Patholytix Preclinical for toxicologic pathology.
Invent, DCU, Dublin 9, Ireland